EORTC GCG MEETING 14 TH AND 15 TH OCTOBER 2011, AMSTERDAM. Location- Plesmanlaan 121. Phone: + 31 (0) FAX: +

Transcription

1 EORTC GCG MEETING 14 TH AND 15 TH OCTOBER 2011, AMSTERDAM. NKI AVL ( THE NETHERLANDS CANCER INSTITUTE AND ANTONI VAN LEEUWENHOEK ZIEKENHUIS ) Location- Plesmanlaan CX Amsterdam Phone: + 31 (0) FAX: + WEBSITE: CONTACTS: LOCAL ORGANISERS: PROF. G.KENTER (G.KENTER@VUMC.NL), DR. KO VAN DER VELDEN, DR. VERSION: 1 SEPTEMBER 15, /11

2 TIMETABLE October 14th 15th, 2011 Room Room name Room name Room Name Day 1 Friday 14 TH OCTOBER :30 12:45 WELCOME & PRACTICAL INFORMATION ON THE MEETING 12:45 14:55 Ovarian TSC Endometrium TSC Cervix, Vulva, Vagina TSC 14:55 15:45 REPORTS ON ONGOING / RECENTLY CLOSED STUDIES 15:45 16:15 COFFEE BREAK 16:15 16:45 SPECIAL SESSION 1 Quality of Life Update 16:45 18:30 GENERAL ASSEMBLY / BUSINESS MEETING Dinner at (TBA) Day 2 Saturday 15 TH OCTOBER :00 09:00 Chemotherapy subcommittee Radiotherapy subcommittee Surgery subcommittee 09:00 10:00 REPORTS FROM TUMOUR SITE COMMITTEES 10:00 10:30 COFFEE BREAK 10:30 11:15 SPECIAL SESSION 2 Report from brainstorm meeting 11:15 13:00 PROTOCOL COMMITTEE Version: 1 15 September /11

3 13.00 OFFICIAL MEETING CLOSES Version: 1 15 September /11

4 Agenda Friday 14, October 2011 WELCOME & PRACTICAL INFORMATION ON THE MEETING 12:30 12:45 G. Kenter, Ko van der Velden, Anneke Westermann TUMOR SITE COMMITTEES (TSC) 12:45 14:55 ROOMS Ovarian TSC (D. Katsaros):. Endometrium TSC (F. Mota):... Cervix, Vulva, Vagina TSC (A. Ferrero):.. OVARIAN TSC Members: D. Katsaros (Chair), I. Vergote, A. Casado, F. Joly, M.E.L. van der Burg, A. Westermann, P. Debruyne REPORTS ON STATUS OF ACCEPTED EORTC GCG TRIALS 1 st line studies: EORTC Randomized phase II of neo-adjuvant chemotherapy with or without IGFR-1 inhibitor (BMS ) in subjects with advanced (FIGO stage IIIc-IV) ovarian, fallopian tube or primary peritoneal cancer (P.Ottevanger, E. Berns, A. Casado). 2 nd line studies: Version: 1 15 September /11

5 EORTC Phase Ib/II of pazopanib and weekly paclitaxel / carboplatin in recurrent platin resistant and refractory ovarian carcinoma (I. Vergote, B. Penninckx, C. Coens). EORTC Phase I/II study with trabectedin-carboplatin in subjects with platinum sensitive ovarian cancer (A. Casado, E. Berns, M.E.L. van der Burg, I. Vergote, N. Ottevanger, C. Coens) EORTC INNOVATYON trial. A MaNGO / ENGOT-ov5 proposal in intermediate platin sensitive ovarian cancer patients (D. Katsaros, A. Casado, B. Marchal, B. Penninckx) REPORTS ON STATUS OF NOT YET ACCEPTED EORTC GCG TRIALS 1 st line studies: New proposals (tbc) ( A. Casado) 2 nd line studies: ENGOT ov14/ago. Pertuzumab in resistant and refractory ovarian cancer patients (I. Vergote) DGCG/NCRI (a GCIG/ENGOT proposal). Vargatef in recurrent clear cell ovarian and endometrial cancer (A. Casado, I. Vergote, N. Ottevanger) A Multicentre Phase 2 Trial of molecular therapy in Advanced/Recurrent Mucinous Ovarian Cancer. (Rosemary Lord / John Green/A. Casado) An academic proposal from MITO: Trabectedin in BRACAness patients (Tbc) NEW PROPOSALS FROM THE FLOOR (cannot be accepted by EORTC GCG PC during meeting!) ENDOMETRIUM TSC Members: F. Mota (Chair), F. Amant, R. Verheijen, E. van der Steen-Banasik, V. D Hondt, A. Nordin, J van der Velden Version: 1 15 September /11

6 REPORTS ON STATUS OF ACCEPTED EORTC GCG TRIALS ENGOT-EN2-DGCG / EORTC study. A phase III trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer. (Danish Gynecologic Cancer Group, DGCG) (DGCG PI: M. Raza Mirza / F. Amant / F. Mota). REPORTS ON STATUS OF NOT YET ACCEPTED EORTC GCG TRIALS NCIC-C / EN.8 proposal: A phase III study of standard therapy versus Ridaforolimus in women with recurrent or metastatic endometrial cancer who have had chemotherapy (NCI-C PI: A. Oza / F. Mota / A. Casado). ENGOT EN -1 / NSGO-NOGGO trial): Phase III trial of carboplatino combined with taxol with or without Vargatef in recurrent endometrial cancer (Mansoor R. Mirza, A. Casado / F. Mota). Proposals from IRCI: International Rare Cancers Initiative from the UK (NCRI/CRUK), USA (NCI) and EORTC (F. Amant / A. Casado). GOG-UC1009: A phase III randomised trial of gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited high grade uterine leiomyosarcoma (F. Amant, F. Mota, A. Casado). CRUK/EORTC/NCI proposal on ESS: Randomised phase II clinical trial to compare aromatase inhibition after surgery or at the point of recurrence in LG ULMS and ESS in the adjuvant setting (Helen Hatcher, F. Amant) EORTC/CRUK/NCI proposal on high grade undifferentiated sarcoma (HGUS): A randomized phase II study evaluating the role of maintenance therapy with pazopanib in HGUS after stabilization or response to chemotherapy following surgery or in metastatic first line treatment (EORTC STBSG PI: I. Ray Coquard / F. Amant / A. Casado / B. Penninckx) NEW PROPOSALS FROM THE FLOOR (cannot be accepted by EORTC GCG PC during meeting!) Version: 1 15 September /11

7 CERVIX, VULVA, VAGINA TSC Members: A. Ferrero (Chair), N. Siddiqui, L. van Doorn, S. Greggi, G. Kenter, J. Kobierski, F. Landoni REPORTS ON STATUS OF ACCEPTED EORTC GCG TRIALS EORTC A randomised phase III trial comparing carboplatin-taxol/cisplatin-topotecan with or without pazopanib as maintenance treatment in advanced cervix cancer (A. Casado, A. Ferrero, B. Penninckx, C. Coens) The SHAPE trial. A proposal for small cervix cancer (Marie Plante s proposal, NCI C; A. Ferrero) REPORTS ON STATUS OF NOT YET ACCEPTED EORTC GCG TRIALS NEW PROPOSALS FROM THE FLOOR (cannot be accepted by EORTC GCG PC during meeting!) New proposals (TBC) A. Ferrero/A. Casado FCING REPORTS ON ONGOING / RECENTLY CLOSED STUDIES 14:55 15:45 ROOMS ONGOING / RECENTLY CLOSED STUDIES EORTC 55041: First line Tarceva trial. I. Vergote / A. Jimeno EORTC 55051: Calypso trial. Calypso sub-studies / publications. A. Ferrero Version: 1 15 September /11

8 NCIC-CTG OV16 EORTC 55012: Outstanding OS data collection. B. Penninckx EORTC 55994: Update on issues. G. Kenter Accrual and new centres (G. Kenter, B. Marchal, B. Penninckx) Update on TR comboined proposal (TRAC review) and paraffin blocks collections (G. Kenter, N. Ottevanger, E. Berns, B. Penninckx) COFFEE BREAK 15:45 16:15 SPECIAL SESSION 1 16:15 16:45 Quality of life in advanced ovarian cancer patients: A randomized phase III study comparing upfront debulking surgery versus neoadjuvant chemotherapy. E. Greimel. Quality of life data (OV28) from the NCIC-CTGOV16-EORTC E. Greimel An update on the vulvar module. E. Greimel. GENERAL ASSEMBLY/BUSINESS MEETING 16:40 18:30 Dr. A. Casado CHAIRMAN REPORT (A. CASADO) EORTC HQ report Dates and venues of the next EORTC Major Meetings March 2012: EORTC 50th Anniversary, Brussels + Gala dinner on 14 March 2012 evening Version: 1 15 September /11

9 EORTC GCG status and pipeline SAC review and response to SAC Scientific Strategy and transversal activities (Pathobiology Group (PBG) / Imaging Group / Elderly Task Force (ETF) New applications/changes in personnel (D. Katsaros/A. Casado) EORTC GCG website update (I. Vergote) Financial report (I. Vergote) Chairman s election Secretary s election FUTURE MEETINGS EORTC GCG Leuven 16th and 17 th March Local organizer: Ignace Vergote Autumn 2012: no proposals have been received yet. GCIG report (A. Casado) ENGOT report (I. Vergote) Saturday October 15, 2011 SUBSPECIALTY COMMITTEES 08:00 09:00 ROOMS Version: 1 15 September /11

10 Chemotherapy subcommittee (N. Ottevanger):... Radiotherapy subcommittee (E. van der Steen):. Surgery subcommittee (S. GReggi)... REPORTS FROM TUMOUR SITE COMMITTEES 09:00 10:00 ROOMS OVARIAN TSC (D. KATSAROS) ENDOMETRIUM TSC (F: MOTA) CERVIX, VULVA, VAGINA TSC (A. FERRERO) COFFEE BREAK 10:00 10:30 SPECIAL SESSION 2 10:30 11:15 Report from brainstorm-meeting on 13 th October 2011 in Brussels (A. Casado / All) Version: 1 15 September /11

11 PROTOCOL COMMITTEE 11:15 13:00 I. Vergote Open for all but only ACTIVE members voting; for voting: 1 vote/centre! Members: I. Vergote (Leuven, Chair PC and Treasurer), D. Katsaros (Torino, Chair OVTSC), A. Casado (Madrid, Chair EORTC GCG), F. Mota (Coimbra, Chair Corpus TSC), A, Ferrero (Torino, Chair Cervix TSC), 5 top accrual F. Joly (Baclesse), N.S. Reed, (Glasgow, Scotland), F. Landoni, (Milano), N.Ottevanger chemotherapy Chair (Nijmegen), J. Kobierski, (Gdansk), P. Debruyne, (Czak), Björn Penninckx (Clinical Research Physician EORTC HQ), S. Greggi (Naples, Surgery Chair), E.M. van der Steen-Banasik (Radiotherapy Chair), M.E.L van der Burg (TR Co-Chair), Corneel Coens (EORTC HQ statistician). OFFICIAL MEETING CLOSES 13:00 NEXT GCG GROUP MEETING: LEUVEN 16TH AND 17 TH MARCH Version: 1 15 September /11